Marinomed Signs Collaboration with Boehringer Ingelheim for Anti-Viral Nasal Spray Against Common Cold

01-Jul-2010 - Austria

Marinomed Biotechnologie GmbH announced that it has signed a licensing agreement with Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia. This nasal spray is based on Marinomed’s anti-viral respiratory technology platform mavirex. Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties. Further financial details were not disclosed.

Dr. Thomas Friedrich, CFO of Marinomed, said: “This is a landmark agreement for Marinomed. We are delighted to commence a long-term collaboration with Boehringer Ingelheim, a perfect partner for the successful marketing of our innovative common cold product worldwide.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances